RedHill Biopharma Ltd. RDHL · Stock Open RedHill Biopharma Ltd. in new tab
RedHill Biopharma Ltd. Analysis (RDHL)
Is RedHill Biopharma Ltd. a good investment? RedHill Biopharma Ltd. (RDHL) is currently trading at 0.6330 USD.
Earnings Schedule: RedHill Biopharma Ltd. is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is 0.03.
Investor FAQ
Does RedHill Biopharma Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is RedHill Biopharma Ltd.?
RedHill Biopharma Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -302.63.
Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Split Date | Split Ratio to 1 |
|---|---|
| March 23, 2023 | 0.030000 |
| Aug. 20, 2024 | 0.040000 |
Community Discussion